<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>MRC Centre for Inflammation Research</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/60DA2095-99E7-46E3-A6E7-2E8B617D96B2"><gtr:id>60DA2095-99E7-46E3-A6E7-2E8B617D96B2</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Kluth</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/97EAC477-E1EB-4797-9320-EE6A5E106DF4"><gtr:id>97EAC477-E1EB-4797-9320-EE6A5E106DF4</gtr:id><gtr:firstName>Lesley</gtr:firstName><gtr:otherNames>Margaret</gtr:otherNames><gtr:surname>Forrester</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4A4415C7-D2BC-450B-BFF1-10C5D20E849C"><gtr:id>4A4415C7-D2BC-450B-BFF1-10C5D20E849C</gtr:id><gtr:firstName>Jeremy</gtr:firstName><gtr:surname>Hughes</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0801235"><gtr:id>126333F9-A850-40CF-B2EA-694D538065A7</gtr:id><gtr:title>ISCHAEMIC ACUTE RENAL FAILURE AND AGE: MODULATION BY ANTI-INFLAMMATORY EMBRYONIC STEM CELL-DERIVED MACROPHAGES</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801235</gtr:grantReference><gtr:abstractText>Renal ischaemia-reperfusion injury follows the restoration of blood flow to kidneys starved of blood following a prolonged lowering of blood pressure caused, for example, by severe infection or trauma. The kidney is infiltrated with white blood cells such as macrophages and many kidney cells die resulting in acute renal failure and the requirement for dialysis. Elderly individuals are more vulnerable to developing acute renal failure as a complication of other illnesses and have a worse outcome compared to younger individuals. This proposal will use state-of-the-art embryonic stem cell technology together with genetic and pharmacological manipulation to generate significant numbers of macrophages that express the anti-inflammatory enzyme hemeoxygenase-1. The nature of these embryonic stem cell-derived macrophages will be scrutinised in cell culture and they will then be administered to mice with ischaemia-reperfusion injury as ?cell therapy? with the prediction that they will significantly protect kidney function. The effect of macrophage cell therapy will be specifically examined in old mice that develop worse renal failure than young mice following a period of diminished blood flow to the kidney. This work will lay the foundation for further studies utilising the potential anti-inflammatory and reparative properties of embryonic stem cell-derived ?designer? macrophages.</gtr:abstractText><gtr:technicalSummary>Renal ischaemia-reperfusion injury (IRI) plays a key role in the development of acute renal failure. Ischaemic acute renal failure remains a serious clinical disorder with significant morbidity and mortality and has an increased incidence and worse outcome in the elderly. Our recent work using a murine model of renal IRI has generated 2 key observations. First, old mice (52 weeks of age) exhibit worse renal failure and increased structural injury following IRI compared to 8 week old adult mice with significantly reduced upregulation of the anti-inflammatory renoprotective enzyme hemeoxygenase-1 (HO-1) evident in old mice. Second, the intravenous administration of macrophages genetically modified to overexpress HO-1 significantly attenuates the development of acute renal failure following renal IRI. We now plan to extend this work by using macrophages generated in vitro from embryonic stem (ES) cells (?designer macrophages?) that have been genetically or pharmacologically manipulated to overexpress HO-1. We will generate ES cell-derived macrophages in vitro and characterise their phenotype using various assays including the cytokine response to inflammatory stimuli, phagocytosis etc. The functional and histological effect of administering modified and control ES cell-derived macrophages to both young and old mice with renal IRI will be determined. Macrophage ?cell therapy? has great potential to alleviate human disease affecting the kidney and ES-derived macrophages are more attractive than monocytes-derived macrophages for several reasons. ES-derived macrophages represent a potentially ?off the shelf? resource that can be rapidly administered to patients without the requirement for human primary monocytes/macrophage cell culture (7 days). It is relatively straightforward to genetically manipulate ES cells such that single or multiple genes may be overexpressed or silenced in the subsequently generated macrophages. The work outlined in this proposal will lay the experimental foundation for using specifically designed ES-derived anti-inflammatory macrophages to ameliorate acute renal injury and inflammation and will have direct relevance to IRI affecting other organs such as liver, heart and brain.</gtr:technicalSummary><gtr:fund><gtr:end>2011-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>449927</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>KRUK Open Day for patient group representatives &amp; researchers</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C956EBD8-BFB0-4B78-BDDE-5ADC0FC83B28</gtr:id><gtr:impact>Team member spoke at an Open day organised by Kidney Research for representatives from patient groups and renal researchers.

This activity was documented of KRUK website</gtr:impact><gtr:outcomeId>bG5zEBCTEYf</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Video on macrophages and kidney disease</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FAAF6851-385E-4B05-8A6E-7E40778CAE3D</gtr:id><gtr:impact>A member of our group gave a video presentation that is available on the Kidney Research UK website to explain the role of macrophages in kidney disease and the potential for macrophages to be used to treat kidney disease.

Kidney Research UK are pleased with video</gtr:impact><gtr:outcomeId>iJNoQdGn1Ve</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>CB1660CE-18E4-41E3-AD1B-384C1E2A191A</gtr:id><gtr:impact>Team member gave a presentation on 'Injury and healing' to science class in a secondary school.

Excellent feedback from school staff with a future visit organised.</gtr:impact><gtr:outcomeId>ZWMgHmWQ35E</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>57330</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD studentship</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Kidney Research UK</gtr:fundingOrg><gtr:id>F48A8BEA-84B0-43C0-9913-79A269991F73</gtr:id><gtr:outcomeId>toP5Z7VF9C40</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC PhD Studentship (MRC Centre for Inflammation Research)</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>236A31A3-A43A-4AEA-92CF-5B05BE91CCEE</gtr:id><gtr:outcomeId>F9D35E36BA80</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>78867</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>The Cunningham Trust</gtr:department><gtr:description>Cunningham Trust Project grant</gtr:description><gtr:end>2013-07-02</gtr:end><gtr:fundingOrg>University of St Andrews</gtr:fundingOrg><gtr:id>08AAAB83-7AAC-4F17-850A-24B00866B255</gtr:id><gtr:outcomeId>iSxn4WoGCAc0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>131000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2014-02-02</gtr:end><gtr:fundingOrg>Kidney Research UK</gtr:fundingOrg><gtr:id>BF78DEAB-FBF3-42EA-94AE-4064DDFA1AB1</gtr:id><gtr:outcomeId>CPfe8A97mR90</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Dr Axton has refined and improved the assay to measure the enzyme activity of the enzyme hemeoxygenase-1. This has involved altering the conditions of the assay and using purified co-factors (rather than liver homogenate as was used previously)</gtr:description><gtr:id>E2153BC9-7AB4-478D-88D8-887C5272C6B9</gtr:id><gtr:impact>We found that the hemeoxygenase-1 assay generally used in the field was somewhat temperamental and variable. The refined assay is now more consistent and reliable and can be used to measure and document the enzymatic activity of both cells and tissues.</gtr:impact><gtr:outcomeId>qY5SU5eAJu3</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Hemeoxygenase-1 bioactivity assay</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have optimised the differentiation protocol to produce robustly phenotyped macrophages from embryonic stem cells (ESDM). Also, we have engineered mouse ES cells carrying a doxycycline-inducible hemeoxygenase-1 (iHO-1) and a mutant inactive form of HO-1 (imutHO-1). These are used to generate iHO-1 ESDMs and imutHO-1 ESDMs for use in 'cell therapy' experiments'</gtr:description><gtr:id>55902CCD-20D4-46CF-889F-430B865EA204</gtr:id><gtr:impact>The ability to reproducible differentiate large numbers of macrophages from genetically engineered or control stem cells will facilitate in vivo and in vitro studies exploring the use of macrophages overexpressing key anti-inflammatory or reparative factors in tissue injury and repair</gtr:impact><gtr:outcomeId>iAZ1CmJxGQn</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>iHO-1 ESDM</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>F1FF55F7-A6BC-403A-B1E0-BAE805BE113A</gtr:id><gtr:title>Cellular orchestrators of renal fibrosis.</gtr:title><gtr:parentPublicationTitle>QJM : monthly journal of the Association of Physicians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4b6022bc63bdd45b1ff903ef32168bc6"><gtr:id>4b6022bc63bdd45b1ff903ef32168bc6</gtr:id><gtr:otherNames>Conway B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1460-2393</gtr:issn><gtr:outcomeId>pm_16608_28_22139500</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7EF4C136-6DA2-402D-9383-3899DDBFBE8F</gtr:id><gtr:title>The renal mononuclear phagocytic system.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7257d794afa00e25b99c78245c746c4d"><gtr:id>7257d794afa00e25b99c78245c746c4d</gtr:id><gtr:otherNames>Nelson PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>pm_16608_28_22135312</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21024FB1-3011-400F-A010-5B3353922931</gtr:id><gtr:title>Induction of hematopoietic differentiation of mouse embryonic stem cells by an AGM-derived stromal cell line is not further enhanced by overexpression of HOXB4.</gtr:title><gtr:parentPublicationTitle>Stem cells and development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/efd4aaeb708858ee50423170cfb64bf3"><gtr:id>efd4aaeb708858ee50423170cfb64bf3</gtr:id><gtr:otherNames>Gordon-Keylock SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1547-3287</gtr:issn><gtr:outcomeId>pm_16608_28_20184433</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3BBBB71D-CA39-4C3F-80DD-E9E87B306A6E</gtr:id><gtr:title>Macrophages expressing heme oxygenase-1 improve renal function in ischemia/reperfusion injury.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7871eeac6beee38c1dd69a1e1093f07"><gtr:id>f7871eeac6beee38c1dd69a1e1093f07</gtr:id><gtr:otherNames>Ferenbach DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>pm_16608_28_20551909</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A23C03E8-87DE-4205-9B5E-FC6F66C036CF</gtr:id><gtr:title>Hemeoxygenase-1 and renal ischaemia-reperfusion injury.</gtr:title><gtr:parentPublicationTitle>Nephron. Experimental nephrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7871eeac6beee38c1dd69a1e1093f07"><gtr:id>f7871eeac6beee38c1dd69a1e1093f07</gtr:id><gtr:otherNames>Ferenbach DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1660-2129</gtr:issn><gtr:outcomeId>sJff1xgEZ5t</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>240C9171-C2EE-4120-9395-9FD99AA0936A</gtr:id><gtr:title>The induction of macrophage hemeoxygenase-1 is protective during acute kidney injury in aging mice.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7871eeac6beee38c1dd69a1e1093f07"><gtr:id>f7871eeac6beee38c1dd69a1e1093f07</gtr:id><gtr:otherNames>Ferenbach DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>PTEWGbBa49h</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28923D32-3A7C-4C4E-92EE-AC4C6D2F706B</gtr:id><gtr:title>Macrophage cell therapy in renal disease.</gtr:title><gtr:parentPublicationTitle>Seminars in nephrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34e5e7060ad5a9f4f42943f3f8fa3e49"><gtr:id>34e5e7060ad5a9f4f42943f3f8fa3e49</gtr:id><gtr:otherNames>Ferenbach D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-9295</gtr:issn><gtr:outcomeId>nUo3qX3LRzh</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801235</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>2EEE0958-6BE1-4D16-B86B-5D954CD37219</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Renal and Urogenital</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>